{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:23:12Z","timestamp":1790652192738,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Many countries are striving to become malaria-free, but global reduction in case estimates has stagnated in recent years. Substandard and falsified medicines may contribute to this lack of progress. Zambia aims to eliminate their annual burden of 1.2 million pediatric malaria cases and 2500 child deaths due to malaria. We examined the health and economic impact of poor-quality antimalarials in Zambia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>An agent-based model, Substandard and Falsified Antimalarial Research Impact (SAFARI), was modified and applied to Zambia. The model was developed to simulate population characteristics, malaria incidence, patient care-seeking, disease progression, treatment outcomes, and associated costs of malaria for children under age five. Zambia-specific demographic, epidemiological, and cost inputs were extracted from the literature. Simulations were run to estimate the health and economic impact of poor-quality antimalarials, the effect of potential artemisinin resistance, and six additional malaria focused policy interventions.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We simulated annual malaria cases among Zambian children under five. At baseline, we found 2610 deaths resulting in $141.5 million in annual economic burden of malaria. We estimated that elimination of substandard and falsified antimalarials would result in an 8.1% (<jats:italic>n<\/jats:italic>\u00a0=\u2009213) reduction in under-five deaths, prevent 937 hospitalizations, and realize $8.5 million in economic savings, annually. Potential artemisinin resistance could further increase deaths by 6.3% (<jats:italic>n<\/jats:italic>\u00a0=\u2009166) and cost an additional $9.7 million every year.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Eliminating substandard and falsified antimalarials is an important step towards a malaria-free Zambia. Beyond the dissemination of insecticide-treated bed nets, indoor residual spraying, and other malaria control measures, attention must also be paid to assure the quality of antimalarial treatments.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12889-020-08852-w","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T16:06:44Z","timestamp":1594310804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model"],"prefix":"10.1186","volume":"20","author":[{"given":"Kathryn D.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen R.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Laing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiluba","family":"Mwila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Sylvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7608-9038","authenticated-orcid":false,"given":"Sachiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"8852_CR1","unstructured":"World Health Organization. World Malaria Report 2018. Geneva: World Health Organization; 2019."},{"key":"8852_CR2","unstructured":"World Health Organization. 10 Facts On Malaria. Geneva: World Health Organization; 2016. Available from: https:\/\/www.who.int\/features\/factfiles\/malaria\/en\/. Cited 2019 April 22."},{"key":"8852_CR3","unstructured":"World Health Organization. World Malaria Report 2019. Geneva: World Health Organization; 2019."},{"key":"8852_CR4","unstructured":"United Nations Children's Fund (UNICEF). Child Mortality Data: Cause of Death. New York: UNICEF; 2019. Available from: https:\/\/data.unicef.org\/topic\/child-survival\/under-five-mortality\/#data. Updated March 1, 2019; Cited 2019 April 22."},{"key":"8852_CR5","unstructured":"President's Malaria Initiative. Country in Focus - Zambia 2019. Available from: https:\/\/www.pmi.gov\/where-we-work\/country-in-focus\/zambia. Cited 2019 April 15."},{"key":"8852_CR6","volume-title":"Zambia Malaria Operational Plan FY 2019","author":"President's Malaria Initiative","year":"2019","unstructured":"President's Malaria Initiative. Zambia Malaria Operational Plan FY 2019. 2019."},{"key":"8852_CR7","unstructured":"The Global Fund. Sourcing & Management of Health Products 2019. Available from: https:\/\/www.theglobalfund.org\/en\/sourcing-management\/quality-assurance\/. Cited 2019 February 12."},{"key":"8852_CR8","unstructured":"ACTwatch Group. ACTwatch study reference document: the Republic of Zambia outlet survey 2014. Washington, DC: ACTwatch Group; 2015."},{"key":"8852_CR9","unstructured":"ACTwatch Group. ACTwatch Study Reference Document: The Republic of Zambia Outlet Survey 2009. Washington DC: ACTwatch Group; 2009.\u00a0."},{"key":"8852_CR10","unstructured":"World Health Organization. Definitions of Substandard and Falsified (SF) Medical Products. Geneva: World Health Organization; 2019. Available from: https:\/\/www.who.int\/medicines\/regulation\/ssffc\/definitions\/en\/. Cited 2019 April 26."},{"issue":"6872","key":"8852_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/415680a","volume":"415","author":"J Sachs","year":"2002","unstructured":"Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415(6872):680\u20135.","journal-title":"Nature."},{"issue":"4","key":"8852_CR12","doi-asserted-by":"publisher","first-page":"e181662","DOI":"10.1001\/jamanetworkopen.2018.1662","volume":"1","author":"S Ozawa","year":"2018","unstructured":"Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Netw Open. 2018;1(4):e181662.","journal-title":"JAMA Netw Open"},{"key":"8852_CR13","unstructured":"Jitka Sabartova AT. Department of Essential Medicines and Pharmaceutical Policies, World Health Organization. In: Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa. Geneva: World Health Organization; 2011."},{"key":"8852_CR14","unstructured":"World Health Organization. Survey of the quality of medicines identified by the UN Commission on life-saving commodities. Geneva: World Health Organization; 2016."},{"key":"8852_CR15","doi-asserted-by":"crossref","unstructured":"Bate R, Mooney L, Hess K. Medicine registration and medicine quality: a preliminary analysis of key cities in emerging markets. Res Rep Trop Med. 2010;1:89\u201393.","DOI":"10.2147\/RRTM.S15199"},{"key":"8852_CR16","unstructured":"Zambia Medicines Regulatory Authority. ZAMRA conducts third rapid medicines quality verification exercises. Lusaka: Zamra; 2019. Available from: http:\/\/www.zamra.co.zm\/zamra-conducts-third-rapid-medicines-quality-verification-exercises\/. Cited 2019 Dec 1."},{"key":"8852_CR17","unstructured":"Zambia Medicines Regulatory Authority. ZAMRA coducts rapid medicines quality verification exercises. Lusaka: Zamra; 2019. Available from: http:\/\/www.zamra.co.zm\/zamra-vonducts-rapid-medicines-quality-verification-exercises\/. Cited 2019 Dec 1."},{"key":"8852_CR18","unstructured":"World Health Organization. A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva: World Health Organization; 2017. Available from\u00a0https:\/\/www.who.int\/medicines\/regulation\/ssffc\/publications\/se-study-sf\/en\/. Cited 2019 June 1."},{"issue":"1","key":"8852_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12936-018-2628-3","volume":"18","author":"S Ozawa","year":"2019","unstructured":"Ozawa S, Evans DR, Higgins CR, Laing SK, Awor P. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study. Malar J. 2019;18(1):5.","journal-title":"Malar J"},{"issue":"8","key":"8852_CR20","doi-asserted-by":"publisher","first-page":"e0217910","DOI":"10.1371\/journal.pone.0217910","volume":"14","author":"SM Beargie","year":"2019","unstructured":"Beargie SM, Higgins CR, Evans DR, Laing SK, Erim D, Ozawa S. The economic impact of substandard and falsified antimalarial medications in Nigeria. PLoS One. 2019;14(8):e0217910.","journal-title":"PLoS One"},{"key":"8852_CR21","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/ncomms6606","volume":"5","author":"LC Okell","year":"2014","unstructured":"Okell LC, Cairns M, Griffin JT, Ferguson NM, Tarning J, Jagoe G, et al. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat Commun. 2014;5:5606.","journal-title":"Nat Commun"},{"issue":"5","key":"8852_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.4269\/ajtmh.18-0334","volume":"100","author":"S Ozawa","year":"2019","unstructured":"Ozawa S, Haynie DG, Bessias S, Laing SK, Ngamasana EL, Yemeke TT, et al. Modeling the economic impact of substandard and falsified Antimalarials in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2019;100(5):1149\u201357.","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"8852_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2471\/BLT.11.085878","volume":"89","author":"Y Lubell","year":"2011","unstructured":"Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumba M, et al. Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull World Health Organ. 2011;89(7):504\u201312.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"8852_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-016-1650-6","volume":"16","author":"F Camponovo","year":"2017","unstructured":"Camponovo F, Bever CA, Galactionova K, Smith T, Penny MA. Incidence and admission rates for severe malaria and their impact on mortality in Africa. Malar J. 2017;16(1):1.","journal-title":"Malar J"},{"key":"8852_CR25","unstructured":"Zambia Statistics Agency, Ministry of Health (MOH) Zambia, and ICF. 2019. Zambia Demographic and Health Survey 2018. Lusaka and Rockville: Zambia Statistics Agency, Ministry of Health, and ICF."},{"issue":"11","key":"8852_CR26","doi-asserted-by":"publisher","first-page":"e7871","DOI":"10.1371\/journal.pone.0007871","volume":"4","author":"Q Bassat","year":"2009","unstructured":"Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Men\u00e9ndez C, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One. 2009;4(11):e7871.","journal-title":"PLoS One"},{"key":"8852_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1475-2875-10-50","volume":"10","author":"M Nambozi","year":"2011","unstructured":"Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated plasmodium falciparum malaria in Zambian children. Malar J. 2011;10:50.","journal-title":"Malar J"},{"issue":"11","key":"8852_CR28","doi-asserted-by":"publisher","first-page":"e1001119","DOI":"10.1371\/journal.pmed.1001119","volume":"8","author":"Four Artemisinin-Based Combinations (4ABC) Study Group","year":"2011","unstructured":"Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8(11):e1001119.","journal-title":"PLoS Med"},{"key":"8852_CR29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/1475-2875-13-430","volume":"13","author":"B Hamainza","year":"2014","unstructured":"Hamainza B, Masaninga F, Moonga H, Mwenda M, Chanda-kapata P, Chalwe V, et al. Therapeutic efficacy of artemether-lumefantrine on treatment of uncomplicated plasmodium falciparum mono-infection in an area of high malaria transmission in Zambia. Malar J. 2014;13:430.","journal-title":"Malar J"},{"issue":"10","key":"8852_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1508606","volume":"374","author":"D Pekyi","year":"2016","unstructured":"Pekyi D, Ampromfi AA, Tinto H, Traor\u00e9-Coulibaly M, Tahita MC, Val\u00e9a I, et al. Four Artemisinin-based treatments in African pregnant women with malaria. N Engl J Med. 2016;374(10):913\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"8852_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-3156.2004.01363.x","volume":"10","author":"E Depoortere","year":"2005","unstructured":"Depoortere E, Guthmann JP, Press\u00e9 J, Sipilanyambe N, Nkandu E, Balkan S, et al. Efficacy and effectiveness of the combination of sulfadoxine\/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia. Tropical Med Int Health. 2005;10(2):139\u201345.","journal-title":"Tropical Med Int Health"},{"key":"8852_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1475-2875-5-75","volume":"5","author":"P Chanda","year":"2006","unstructured":"Chanda P, Hawela M, Kango M, Sipilanyambe N. Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Coartesiane) for the treatment of uncomplicated plasmodium falciparum in children in Zambia. Malar J. 2006;5:75.","journal-title":"Malar J"},{"issue":"1","key":"8852_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053772","volume":"8","author":"A Yeka","year":"2013","unstructured":"Yeka A, Tibenderana J, Achan J, D'Alessandro U, Talisuna AO. Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children. PLoS One. 2013;8(1):e53772.","journal-title":"PLoS One"},{"issue":"6","key":"8852_CR34","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1128\/AAC.01727-10","volume":"55","author":"WJ Verret","year":"2011","unstructured":"Verret WJ, Arinaitwe E, Wanzira H, Bigira V, Kakuru A, Kamya M, et al. Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria. Antimicrob Agents Chemother. 2011;55(6):2629\u201335.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"8852_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1365-3156.2003.01157.x","volume":"9","author":"E Depoortere","year":"2004","unstructured":"Depoortere E, Guthmann JP, Sipilanyambe N, Nkandu E, Fermon F, Balkan S, et al. Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia. Tropical Med Int Health. 2004;9(1):62\u20137.","journal-title":"Tropical Med Int Health"},{"issue":"8","key":"8852_CR36","first-page":"928","volume":"12","author":"A Aspler","year":"2008","unstructured":"Aspler A, Menzies D, Oxlade O, Banda J, Mwenge L, Godfrey-Faussett P, et al. Cost of tuberculosis diagnosis and treatment from the patient perspective in Lusaka, Zambia. Int J Tuberc Lung Dis. 2008;12(8):928\u201335.","journal-title":"Int J Tuberc Lung Dis"},{"key":"8852_CR37","unstructured":"World Health Organization. Health Service Delivery Costs Geneva, Switzerland 2010. Available from: https:\/\/www.who.int\/choice\/cost-effectiveness\/inputs\/health_service\/en\/. Cited 2019 February 11."},{"key":"8852_CR38","unstructured":"The World Bank. Zambia 2019. Available from: https:\/\/data.worldbank.org\/country\/zambia. Cited 2019 Feb 11."},{"key":"8852_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1478-7547-7-5","volume":"7","author":"P Chanda","year":"2009","unstructured":"Chanda P, Castillo-Riquelme M, Masiye F. Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia. Cost Eff Resour Alloc. 2009;7:5.","journal-title":"Cost Eff Resour Alloc"},{"key":"8852_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1475-2875-6-21","volume":"6","author":"P Chanda","year":"2007","unstructured":"Chanda P, Masiye F, Chitah B, Sipilanyambe N, Hawela M, Banda P, et al. A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia. Malar J. 2007;6:21.","journal-title":"Malar J"},{"issue":"1","key":"8852_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4269\/ajtmh.13-0019","volume":"90","author":"AB Comfort","year":"2014","unstructured":"Comfort AB, van Dijk JH, Mharakurwa S, Stillman K, Gabert R, Korde S, et al. Hospitalizations and costs incurred at the facility level after scale-up of malaria control: pre-post comparisons from two hospitals in Zambia. Am J Trop Med Hyg. 2014;90(1):20\u201332.","journal-title":"Am J Trop Med Hyg"},{"key":"8852_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1475-2875-10-159","volume":"10","author":"P Chanda","year":"2011","unstructured":"Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F. Relative costs and effectiveness of treating uncomplicated malaria in two rural districts in Zambia: implications for nationwide scale-up of home-based management. Malar J. 2011;10:159.","journal-title":"Malar J"},{"key":"8852_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1475-2875-13-128","volume":"13","author":"B Hamainza","year":"2014","unstructured":"Hamainza B, Moonga H, Sikaala CH, Kamuliwo M, Bennett A, Eisele TP, et al. Monitoring, characterization and control of chronic, symptomatic malaria infections in rural Zambia through monthly household visits by paid community health workers. Malar J. 2014;13:128.","journal-title":"Malar J"},{"key":"8852_CR44","unstructured":"Worldwide Antimalarial Resistance Network. WWARN tracker 2019. Available from: https:\/\/www.wwarn.org\/. Cited 2019 Feb 11."},{"key":"8852_CR45","unstructured":"United States Treasury. Current Rates 2019. Available from: https:\/\/fiscal.treasury.gov\/reports-statements\/treasury-reporting-rates-exchange\/. Cited 2019 Feb 11."},{"key":"8852_CR46","unstructured":"The World Bank. Inflation, consumer prices Zambia 2019. Available from: https:\/\/data.worldbank.org\/indicator\/FP.CPI.TOTL.ZG?locations=ZM. Cited 2019 Feb 11."},{"key":"8852_CR47","unstructured":"World Health Organization. Responding to antimalarial drug resistance 2018. Available from: https:\/\/www.who.int\/malaria\/areas\/drug_resistance\/overview\/en\/. Updated 20 April 2018; cited 2019 Jan 4."},{"key":"8852_CR48","unstructured":"Knoema. Zambia - Total population aged 0\u20134 years 2018. Available from: https:\/\/knoema.com\/search?query=Zambia%20population%200-4."},{"key":"8852_CR49","unstructured":"Kiefer S, Patouillard E, Palafox B, Tougher S, Mpasela F, Goodman C, et al. A Qualitative Assessment of the Private Sector Antimalarial Distribution Chain in Zambia, 2009. Nairobi: ACTwatch project; 2012."},{"key":"8852_CR50","unstructured":"Global Pharma Health Fund. The GPHF-minilab: protection against counterfeit medicines. Giessen: Global Pharma Health Fund. Available from: https:\/\/www.gphf.org\/en\/minilab\/. Cited 2020 January 15."},{"issue":"1","key":"8852_CR51","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1186\/s12889-016-3460-8","volume":"16","author":"BM Hamooya","year":"2016","unstructured":"Hamooya BM, Chongwe G, Dambe R, Halwiindi H. Treatment-seeking behaviour for childhood fever among caretakers of Chivuna and Magoye rural communities of Mazabuka District, Zambia: a longitudinal study. BMC Public Health. 2016;16(1):762.","journal-title":"BMC Public Health"},{"issue":"1","key":"8852_CR52","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12913-017-2180-9","volume":"17","author":"T Bright","year":"2017","unstructured":"Bright T, Felix L, Kuper H, Polack S. A systematic review of strategies to increase access to health services among children in low and middle income countries. BMC Health Serv Res. 2017;17(1):252.","journal-title":"BMC Health Serv Res"},{"key":"8852_CR53","doi-asserted-by":"publisher","first-page":"l5327","DOI":"10.1136\/bmj.l5327","volume":"366","author":"E Pisani","year":"2019","unstructured":"Pisani E. How moves towards universal health coverage could encourage poor quality drugs: an essay by Elizabeth Pisani. BMJ. 2019;366:l5327.","journal-title":"BMJ."},{"issue":"3","key":"8852_CR54","first-page":"343","volume":"29","author":"Y Xie","year":"2011","unstructured":"Xie Y. Values and limitations of statistical models. Res Soc Stratif Mobil. 2011;29(3):343\u20139.","journal-title":"Res Soc Stratif Mobil"},{"issue":"1","key":"8852_CR55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pbiomolbio.2013.03.008","volume":"113","author":"J Gomez-Ramirez","year":"2013","unstructured":"Gomez-Ramirez J, Sanz R. On the limitations of standard statistical modeling in biological systems: a full Bayesian approach for biology. Prog Biophys Mol Biol. 2013;113(1):80\u201391.","journal-title":"Prog Biophys Mol Biol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-08852-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:09:06Z","timestamp":1625785746000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-08852-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["8852"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-08852-w","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"4 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1083"}}